ArticleJournal of the American Chemical Society2026
A Direct-to-Biology Amine-Acid Amination for Rapid Phenotypic Profiling of Lysosomotropic Natural Products.
Article in Journal of the American Chemical Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Natural products (NPs) are foundational to drug discovery, owing to their diverse molecular scaffolds and novel bioactivities. However, optimizing NPs for optimal bioactivity and improved drug properties is hindered by material scarcity and labor-intensive purification processes. Here, we present an automated ultrahigh-throughput experimentation (ultraHTE) and direct-to-biology (D2B) platform that enables rapid structure-activity relationship (SAR) mapping from miniaturized libraries of synthetic NP analogues, unlocking NPs as a viable starting point for late-stage diversification in drug-lead optimization. Starting from leelamine, a conifer resin-derived tricyclic diterpene with prostate cancer antiproliferative activity, we synthesized leelamine analogues in a 1536-well format, achieving a 73% success rate while consuming only 0.03 mg of NP per reaction. Key to success was the development of a platinum-catalyzed amine-acid reductive amination reaction, which performed well on both amine and complementary acid-derived NPs, in a so-called Janus strategy which more than doubled the accessible chemical space. Direct phenotypic screening in LNCaP cells enabled rapid identification of potent, cell-permeable analogues with robust quality control achieved through iterative resynthesis on preparative scale. SAR insights revealed two key substitution patterns driving potency based on 4-methoxyphenyl and 3-indolyl derivatives. Mechanistic studies─including androgen receptor binding, chemoproteomics, and a lysosomal cholesterol colocalization assay─demonstrated distinct modes of action for optimized analogues compared to leelamine. Collectively, this amine-acid amination-based D2B platform showcases accelerated SAR elucidation from minimal material and cellular profiling, unlocking a framework for mechanism-driven lead discovery in NP chemical space.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.